Manabu Ohashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manabu Ohashi has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Takeshi Sano
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
47 shared publicationsSouya Nunobe
Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan
37 shared publicationsRie Makuuchi
Department of Gastroenterological Surgery Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan
31 shared publicationsKoshi Kumagai
Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
29 shared publicationsSatoshi Ida
Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
29 shared publications- Souya Nunobe
Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
29 shared publications
Latest Publications
- 27 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111513
Unexpected proximal tumor extension as a predictor of poor survival after distal gastrectomy for locally advanced gastric cancer
- 27 February 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (4) , 111513
Unexpected proximal tumor extension as a predictor of poor survival after distal gastrectomy for locally advanced gastric cancer
- Open Access
- 29 November 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (3) , 663-670
Prospective Feasibility Study of Laparoscopic and Robotic Distal Gastrectomy for Advanced Gastric Cancer to Verify the Safety of Surgical Proximal Margins
Ensuring an adequate surgical proximal margin (SPM) is crucial in radical gastrectomy for gastric cancer. However, the lack of tactile feedback in laparoscopic distal gastrectomy (LDG) and robotic distal gastrectomy (RDG) poses challenges in precisely determining tumor boundaries, particularly in advanced gastric cancer, where tumor infiltration may extend beyond endoscopically detectable margins. This single‐center prospective study evaluates the safety of SPM in LDG and RDG for advanced gastric cancer. Methods: Patients with cT1N2–3/cT2N0–3/cT3‐4aN0 gastric cancer were enrolled. The primary endpoint was the incidence of SPM < 20 mm. The planned sample size was 130, providing 90% power under the hypothesis of an expected incidence of 10% and a threshold of 20%, using an exact binomial test at a 5% one‐sided significance level. Results: Between December 2017 and December 2021, 130 eligible patients were enrolled. Among them, 32 (24.6%) underwent RDG, and 5 (3.8%) required conversion to open surgery. The median SPM length was 52 mm (IQR: 40–76 mm). The incidence of SPM < 20 mm was 3.1% (4/130; 95% CI, 0%–6.9%), below the predefined threshold of 20% and predicted value of 10%. Two patients (1.5%) had positive margins. The overall complication rate was 10.4%, with intra‐abdominal infectious complications occurring in 3.1%. No Clavien–Dindo grade IVA or higher complications were observed. Conclusions: LDG and RDG can achieve a safe SPM in advanced gastric cancer, with a low incidence of SPM < 20 mm, ensuring a very low risk of positive SPM.
- 29 November 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (3) , 663-670
Open AccessProspective Feasibility Study of Laparoscopic and Robotic Distal Gastrectomy for Advanced Gastric Cancer to Verify the Safety of Surgical Proximal Margins
Ensuring an adequate surgical proximal margin (SPM) is crucial in radical gastrectomy for gastric cancer. However, the lack of tactile feedback in laparoscopic distal gastrectomy (LDG) and robotic distal gastrectomy (RDG) poses challenges in precisely determining tumor boundaries, particularly in advanced gastric cancer, where tumor infiltration may extend beyond endoscopically detectable margins. This single‐center prospective study evaluates the safety of SPM in LDG and RDG for advanced gastric cancer. Methods: Patients with cT1N2–3/cT2N0–3/cT3‐4aN0 gastric cancer were enrolled. The primary endpoint was the incidence of SPM < 20 mm. The planned sample size was 130, providing 90% power under the hypothesis of an expected incidence of 10% and a threshold of 20%, using an exact binomial test at a 5% one‐sided significance level. Results: Between December 2017 and December 2021, 130 eligible patients were enrolled. Among them, 32 (24.6%) underwent RDG, and 5 (3.8%) required conversion to open surgery. The median SPM length was 52 mm (IQR: 40–76 mm). The incidence of SPM < 20 mm was 3.1% (4/130; 95% CI, 0%–6.9%), below the predefined threshold of 20% and predicted value of 10%. Two patients (1.5%) had positive margins. The overall complication rate was 10.4%, with intra‐abdominal infectious complications occurring in 3.1%. No Clavien–Dindo grade IVA or higher complications were observed. Conclusions: LDG and RDG can achieve a safe SPM in advanced gastric cancer, with a low incidence of SPM < 20 mm, ensuring a very low risk of positive SPM.
- Open Access
- 12 October 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (2) , 414-423
Postoperative Impact of Anti‐Inflammatory Drug on Cancer Recurrence in Patients With Locally Advanced Gastric Cancer After Curative Gastrectomy: A Pilot Retrospective Study
Background: Elevated postoperative inflammation is associated with reduced recurrence‐free survival (RFS) after gastrectomy in patients with gastric cancer, independent of postoperative complications. The effect of the administration of anti‐inflammatory drugs immediately after gastrectomy on prolonging RFS in patients with gastric cancer has not been fully investigated. In this study, we aimed to investigate the effects of anti‐inflammatory drugs on the long‐term recurrence rates of gastric cancer after radical resection. Methods: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStage II–III gastric cancer between May 2006 and March 2017. We performed propensity score matching using a logistic regression model to adjust for patient background, compared RFS, and used Cox proportional hazard regression to identify prognostic factors. Results: Median duration of follow‐up was 62 months. After matching, 591 patients were included in the untreated group, and 197 were included in the group treated with anti‐inflammatory drugs. RFS was no significant difference in the two groups (5‐year RFS: treated group, 73.2%; untreated group, 68.4%; p = 0.246), but peritoneal recurrence was significantly lower in the treated group ( p = 0.028). Multivariate analyses showed that anti‐inflammatory drugs were independent prognostic factors for recurrence‐free survival (hazard ratio, 0.751; 95% confidence interval, 0.569–0.992; p = 0.044). In the subgroup analysis, using multivariate analysis for recurrence‐free survival, anti‐inflammatory drugs were more effective in patients with pStage III than in those with pStage II disease. Conclusion: Anti‐inflammatory drug administration after radical resection may prolong recurrence‐free survival in patients with pStage III gastric cancer.
- 12 October 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (2) , 414-423
Open AccessPostoperative Impact of Anti‐Inflammatory Drug on Cancer Recurrence in Patients With Locally Advanced Gastric Cancer After Curative Gastrectomy: A Pilot Retrospective Study
Background: Elevated postoperative inflammation is associated with reduced recurrence‐free survival (RFS) after gastrectomy in patients with gastric cancer, independent of postoperative complications. The effect of the administration of anti‐inflammatory drugs immediately after gastrectomy on prolonging RFS in patients with gastric cancer has not been fully investigated. In this study, we aimed to investigate the effects of anti‐inflammatory drugs on the long‐term recurrence rates of gastric cancer after radical resection. Methods: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStage II–III gastric cancer between May 2006 and March 2017. We performed propensity score matching using a logistic regression model to adjust for patient background, compared RFS, and used Cox proportional hazard regression to identify prognostic factors. Results: Median duration of follow‐up was 62 months. After matching, 591 patients were included in the untreated group, and 197 were included in the group treated with anti‐inflammatory drugs. RFS was no significant difference in the two groups (5‐year RFS: treated group, 73.2%; untreated group, 68.4%; p = 0.246), but peritoneal recurrence was significantly lower in the treated group ( p = 0.028). Multivariate analyses showed that anti‐inflammatory drugs were independent prognostic factors for recurrence‐free survival (hazard ratio, 0.751; 95% confidence interval, 0.569–0.992; p = 0.044). In the subgroup analysis, using multivariate analysis for recurrence‐free survival, anti‐inflammatory drugs were more effective in patients with pStage III than in those with pStage II disease. Conclusion: Anti‐inflammatory drug administration after radical resection may prolong recurrence‐free survival in patients with pStage III gastric cancer.
- Open Access
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Oncological impact of unexpected horizontal tumour spread in oesophagogastric junction cancer
Background: Unexpected horizontal tumour spread towards the proximal and distal margins complicates the assessment of surgical margins in oesophagogastric junction (OGJ) cancer. Its impact on oncological outcomes remains unclear. Methods: This study retrospectively analysed patients with OGJ adenocarcinoma undergoing proximal or total gastrectomy. Unexpected horizontal tumour spread was measured as the discrepancy between gross and pathological margins proximally (ΔPM) and distally (ΔDM). Clinicopathological features, recurrence-free survival (RFS), and overall survival (OS) were evaluated based on ΔPM and ΔDM. Results: Based on cut-off values identified by time-dependent receiver operating characteristic curve analysis (ΔPM, 8 mm; ΔDM, 3 mm) in 197 patients, patients were classified into four groups: short; long ΔPM; long ΔDM; and both long ΔPM and ΔDM (both-long). RFS was best in the short group and worst in the both-long group. The long ΔPM and long ΔDM groups had intermediate and comparable RFS. Subsequently, patients were categorized into two groups: a short group and a long group, which included patients in the long ΔPM, long ΔDM, and both-long groups. The type of infiltrative growth and postoperative recurrence were significantly associated with the long group. Moreover, the long group had significantly worse RFS and OS than the short group. Multivariate Cox regression analyses identified the long group as an independent risk factor for both RFS and OS. Patients in the long group with clinical lymph node metastasis or tumours located in the proximal 2-cm segment of the OGJ, predominantly in the proximal rather than distal 2-cm segment of the OGJ, or equal involvement in both areas had markedly worse survival outcomes. Conclusion: Unexpected horizontal tumour spread, represented by ΔPM and ΔDM, is a strong predictor of poor survival and recurrence in OGJ cancer. Intraoperative assessment of ΔPM and ΔDM using frozen section analysis may be useful in guiding additional resections, particularly when combined with other predictive factors.
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Open AccessOncological impact of unexpected horizontal tumour spread in oesophagogastric junction cancer
Background: Unexpected horizontal tumour spread towards the proximal and distal margins complicates the assessment of surgical margins in oesophagogastric junction (OGJ) cancer. Its impact on oncological outcomes remains unclear. Methods: This study retrospectively analysed patients with OGJ adenocarcinoma undergoing proximal or total gastrectomy. Unexpected horizontal tumour spread was measured as the discrepancy between gross and pathological margins proximally (ΔPM) and distally (ΔDM). Clinicopathological features, recurrence-free survival (RFS), and overall survival (OS) were evaluated based on ΔPM and ΔDM. Results: Based on cut-off values identified by time-dependent receiver operating characteristic curve analysis (ΔPM, 8 mm; ΔDM, 3 mm) in 197 patients, patients were classified into four groups: short; long ΔPM; long ΔDM; and both long ΔPM and ΔDM (both-long). RFS was best in the short group and worst in the both-long group. The long ΔPM and long ΔDM groups had intermediate and comparable RFS. Subsequently, patients were categorized into two groups: a short group and a long group, which included patients in the long ΔPM, long ΔDM, and both-long groups. The type of infiltrative growth and postoperative recurrence were significantly associated with the long group. Moreover, the long group had significantly worse RFS and OS than the short group. Multivariate Cox regression analyses identified the long group as an independent risk factor for both RFS and OS. Patients in the long group with clinical lymph node metastasis or tumours located in the proximal 2-cm segment of the OGJ, predominantly in the proximal rather than distal 2-cm segment of the OGJ, or equal involvement in both areas had markedly worse survival outcomes. Conclusion: Unexpected horizontal tumour spread, represented by ΔPM and ΔDM, is a strong predictor of poor survival and recurrence in OGJ cancer. Intraoperative assessment of ΔPM and ΔDM using frozen section analysis may be useful in guiding additional resections, particularly when combined with other predictive factors.
- Open Access
- 31 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (1) , 77-86
Optimal Cutoff Size of Large Borrmann Type III Gastric Cancer: Is 8 cm Accurate in Predicting Survival and Incidence of Peritoneal Metastasis?
Background: Large type III gastric cancer (GC) ≥ 8 cm has conventionally been categorized with type IV GC in Japan, leading to alternative treatment strategies such as neoadjuvant chemotherapy and staging laparoscopy (SL). However, whether 8 cm is the correct cutoff remains unclear. Methods: We retrospectively analyzed patients clinically diagnosed with advanced GC who underwent surgery at our department. Patients were classified by Borrmann type, and clinicopathological characteristics including survival outcomes and peritoneal metastasis incidence were analyzed based on tumor size to determine the optimal cutoff for large type III GC. Results: Tumor size correlated with overall survival in type III GC. Although hazard ratios (HRs) for “large” and “small” type III vs. type IV remained comparable up to the 8 cm cutoff (0.60 and 0.41, respectively), HR for “large” type III GC increases sharply to 0.74 with a 10 cm cutoff. Subgroup analysis based on histological subtype revealed similar results in the undifferentiated type. Conversely, a larger cutoff value appeared more appropriate for the differentiated type. The largest difference in the incidence of peritoneal metastasis was observed with a 6 cm cutoff (36.1% in “large” type III and 10.2% in “small” type III), and similar results were observed in the undifferentiated type at the same cutoff. Conclusions: In terms of survival, a 10 cm cutoff may more accurately define large type III GC than the conventional 8 cm. However, if surgeons intend to identify peritoneal metastasis by SL, type III GC ≥ 6 cm could be a possible candidate.
- 31 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (1) , 77-86
Open AccessOptimal Cutoff Size of Large Borrmann Type III Gastric Cancer: Is 8 cm Accurate in Predicting Survival and Incidence of Peritoneal Metastasis?
Background: Large type III gastric cancer (GC) ≥ 8 cm has conventionally been categorized with type IV GC in Japan, leading to alternative treatment strategies such as neoadjuvant chemotherapy and staging laparoscopy (SL). However, whether 8 cm is the correct cutoff remains unclear. Methods: We retrospectively analyzed patients clinically diagnosed with advanced GC who underwent surgery at our department. Patients were classified by Borrmann type, and clinicopathological characteristics including survival outcomes and peritoneal metastasis incidence were analyzed based on tumor size to determine the optimal cutoff for large type III GC. Results: Tumor size correlated with overall survival in type III GC. Although hazard ratios (HRs) for “large” and “small” type III vs. type IV remained comparable up to the 8 cm cutoff (0.60 and 0.41, respectively), HR for “large” type III GC increases sharply to 0.74 with a 10 cm cutoff. Subgroup analysis based on histological subtype revealed similar results in the undifferentiated type. Conversely, a larger cutoff value appeared more appropriate for the differentiated type. The largest difference in the incidence of peritoneal metastasis was observed with a 6 cm cutoff (36.1% in “large” type III and 10.2% in “small” type III), and similar results were observed in the undifferentiated type at the same cutoff. Conclusions: In terms of survival, a 10 cm cutoff may more accurately define large type III GC than the conventional 8 cm. However, if surgeons intend to identify peritoneal metastasis by SL, type III GC ≥ 6 cm could be a possible candidate.
- 7 June 2025
- Published by Springer Nature in Surgery Today
- Vol. 55 (8) , 1013-1023
Maintenance of resection margins in gastrectomy for cancer: simple in procedure, influential in survival—current status and literature review on optimal lengths and positive margins
Purpose The prognostic significance of the proximal margin length (PML) and positive resection margins (PRMs) in gastric cancer (GC) remains controversial. International guidelines for PML differ widely, reflecting a lack of consensus on optimal surgical margins. While positive RMs are associated with poor survival, their impact varies according to the tumor stage and nodal involvement. Methods A comprehensive review of the relevant literature was conducted to evaluate guideline recommendations on PML, factors influencing pathological negativity, the prognostic impact of PMLs and PRMs, and treatment strategies for cases with PRMs, including incidence, additional resection, and adjuvant therapy. Results A tumor-specific approach is essential for determining the optimal PML. When achieving the recommended PML is challenging, an intraoperative frozen section (IFS) analysis helps to ensure negative margins while minimizing unnecessary resection. PRMs are associated with poor survival, particularly in early stage GC, whereas their impact in advanced-stage GC is often overshadowed by systemic disease progression. Additional resection may benefit the selection of patients with early stage GC; however, its role in advanced-stage GC remains uncertain. Conclusion Further research should refine surgical decision-making, optimize PML thresholds, and evaluate the role of multimodal treatment strategies, including molecular profiling and intraoperative imaging techniques. Effective management of PRMs requires balancing oncological safety with functional preservation.
- 7 June 2025
- Published by Springer Nature in Surgery Today
- Vol. 55 (8) , 1013-1023
Maintenance of resection margins in gastrectomy for cancer: simple in procedure, influential in survival—current status and literature review on optimal lengths and positive margins
Purpose The prognostic significance of the proximal margin length (PML) and positive resection margins (PRMs) in gastric cancer (GC) remains controversial. International guidelines for PML differ widely, reflecting a lack of consensus on optimal surgical margins. While positive RMs are associated with poor survival, their impact varies according to the tumor stage and nodal involvement. Methods A comprehensive review of the relevant literature was conducted to evaluate guideline recommendations on PML, factors influencing pathological negativity, the prognostic impact of PMLs and PRMs, and treatment strategies for cases with PRMs, including incidence, additional resection, and adjuvant therapy. Results A tumor-specific approach is essential for determining the optimal PML. When achieving the recommended PML is challenging, an intraoperative frozen section (IFS) analysis helps to ensure negative margins while minimizing unnecessary resection. PRMs are associated with poor survival, particularly in early stage GC, whereas their impact in advanced-stage GC is often overshadowed by systemic disease progression. Additional resection may benefit the selection of patients with early stage GC; however, its role in advanced-stage GC remains uncertain. Conclusion Further research should refine surgical decision-making, optimize PML thresholds, and evaluate the role of multimodal treatment strategies, including molecular profiling and intraoperative imaging techniques. Effective management of PRMs requires balancing oncological safety with functional preservation.
- 14 April 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (4) , 725-726
Letter to the editor: appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ
- 14 April 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (4) , 725-726
Letter to the editor: appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ
- 13 March 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (7) , 109762
Worse oncological impact of preoperative anemia in patients with locally advanced gastric cancer after curative gastrectomy: A retrospective cohort study
- 13 March 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (7) , 109762
Worse oncological impact of preoperative anemia in patients with locally advanced gastric cancer after curative gastrectomy: A retrospective cohort study
- Open Access
- 4 March 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 698-710
Prognostic impact of postoperative fixed‐point inflammation in patients with gastric cancer after curative gastrectomy: A validation cohort study
Background: This study aimed to determine the cutoff values of C‐reactive protein (CRP) on postoperative day 3 to predict poor overall survival (OS) in men and women with gastric cancer after radical gastrectomy.Methods: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStages I–III gastric cancer between May 2006 and March 2017. The patients were randomly divided 6:4 into a training set, which examined the cutoff values for CRP, and a validation set, which validated the cutoff values. Patients with a CRP level higher than the cutoff value were defined as the high‐CRP group, and those with a CRP level lower than the cutoff value were defined as the low‐CRP group. We compared the OS of the high and low CRP groups using the log‐rank test and identified prognostic factors using Cox proportional hazards regression analysis.Results: We examined the cutoff values of CRP, which were 19.1 mg/dL for men and 8.1 mg/dL for women. The median follow‐up duration was 66 months. The high‐CRP group had poorer OS than the low‐CRP group (p < 0.001). Multivariate analyses showed that a high CRP level was an independent poor prognostic factor for OS in all patients (hazard ratio, 1.356; 95% confidence interval, 1.168–1.576; p < 0.001), not only in patients without postoperative complications (p = 0.001) but also in patients with postoperative complications (p = 0.023).Conclusion: This study demonstrated that a high postoperative CRP was an independent poor prognostic factor for OS in patients with gastric cancer after radical gastrectomy.
- 4 March 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (4) , 698-710
Open AccessPrognostic impact of postoperative fixed‐point inflammation in patients with gastric cancer after curative gastrectomy: A validation cohort study
Background: This study aimed to determine the cutoff values of C‐reactive protein (CRP) on postoperative day 3 to predict poor overall survival (OS) in men and women with gastric cancer after radical gastrectomy.Methods: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStages I–III gastric cancer between May 2006 and March 2017. The patients were randomly divided 6:4 into a training set, which examined the cutoff values for CRP, and a validation set, which validated the cutoff values. Patients with a CRP level higher than the cutoff value were defined as the high‐CRP group, and those with a CRP level lower than the cutoff value were defined as the low‐CRP group. We compared the OS of the high and low CRP groups using the log‐rank test and identified prognostic factors using Cox proportional hazards regression analysis.Results: We examined the cutoff values of CRP, which were 19.1 mg/dL for men and 8.1 mg/dL for women. The median follow‐up duration was 66 months. The high‐CRP group had poorer OS than the low‐CRP group (p < 0.001). Multivariate analyses showed that a high CRP level was an independent poor prognostic factor for OS in all patients (hazard ratio, 1.356; 95% confidence interval, 1.168–1.576; p < 0.001), not only in patients without postoperative complications (p = 0.001) but also in patients with postoperative complications (p = 0.023).Conclusion: This study demonstrated that a high postoperative CRP was an independent poor prognostic factor for OS in patients with gastric cancer after radical gastrectomy.
- 17 January 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (3) , 493-500
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer
Background Ensuring a pathologically negative distal margin (DM) and preserving a larger remnant stomach is important for proximal gastrectomy (PG) in patients with esophagogastric junction (EGJ) cancer. However, the minimum DM length for ensuring negative margins has not been identified. Methods We enrolled patients undergoing PG or total gastrectomy for EGJ cancer. A parameter ΔDM, representing the pathological extension distally beyond the gross tumor boundary, was evaluated. The maximum ΔDM, which indicates the minimum length ensuring a pathologically negative DM, was determined in all patients. Subgroup analyses were performed according to factors associated with ΔDM > 10 mm. The possible incidences of pathologically positive DM based on gross DM length were also calculated. Results Among 253 eligible patients, the maximum ΔDM was 55 mm. Growth and pathological types were significantly associated with ΔDM > 10 mm. In subgroup analyses, the maximum ΔDM was 30/20/55 mm for the superficial/expansive/infiltrative growth types, and 55/40 mm for the differentiated/undifferentiated types. In the infiltrative growth type alone, the maximum ΔDM remained 55/40 mm for the differentiated/undifferentiated types. However, even if the gross DM length was reduced to 30 mm, the possible incidence of pathologically positive DM only increased to 2.6% in the infiltrative differentiated type. Conclusion We recommend a minimum DM length of 30/20/55 mm for the superficial/expansive/ infiltrative growth types. Specifically in the infiltrative growth type, we alternatively recommend 30/40 mm for the differentiated/undifferentiated types, with a mandatory intraoperative frozen section analysis. Mini-abstract This study proposes a distal margin length for safe resection of esophagogastric junction cancer, ensuring pathologically negative margins while preserving a larger remnant stomach, based on growth and pathological types.
- 17 January 2025
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (3) , 493-500
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer
Background Ensuring a pathologically negative distal margin (DM) and preserving a larger remnant stomach is important for proximal gastrectomy (PG) in patients with esophagogastric junction (EGJ) cancer. However, the minimum DM length for ensuring negative margins has not been identified. Methods We enrolled patients undergoing PG or total gastrectomy for EGJ cancer. A parameter ΔDM, representing the pathological extension distally beyond the gross tumor boundary, was evaluated. The maximum ΔDM, which indicates the minimum length ensuring a pathologically negative DM, was determined in all patients. Subgroup analyses were performed according to factors associated with ΔDM > 10 mm. The possible incidences of pathologically positive DM based on gross DM length were also calculated. Results Among 253 eligible patients, the maximum ΔDM was 55 mm. Growth and pathological types were significantly associated with ΔDM > 10 mm. In subgroup analyses, the maximum ΔDM was 30/20/55 mm for the superficial/expansive/infiltrative growth types, and 55/40 mm for the differentiated/undifferentiated types. In the infiltrative growth type alone, the maximum ΔDM remained 55/40 mm for the differentiated/undifferentiated types. However, even if the gross DM length was reduced to 30 mm, the possible incidence of pathologically positive DM only increased to 2.6% in the infiltrative differentiated type. Conclusion We recommend a minimum DM length of 30/20/55 mm for the superficial/expansive/ infiltrative growth types. Specifically in the infiltrative growth type, we alternatively recommend 30/40 mm for the differentiated/undifferentiated types, with a mandatory intraoperative frozen section analysis. Mini-abstract This study proposes a distal margin length for safe resection of esophagogastric junction cancer, ensuring pathologically negative margins while preserving a larger remnant stomach, based on growth and pathological types.